Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder.
Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder.
复制标题
DOI：
10.1080/14740338.2018.1395854
复制
发表时间：
2018-01
影响因子：
3.1
通讯作者：
Yeomans BL
中科院分区：
文献类型：
--
作者：
Bello NT;Yeomans BL
饮食失调是一组具有终生并发症和高复发率的精神疾病。患有进食障碍的人往往被污名化，临床医生的治疗选择有限。药物治疗有可能提高长期依从性和患者对饮食障碍治疗的承诺。这篇综述将考察FDA批准的治疗神经性暴食症(BN)和暴饮暴食障碍(BED)的药物的有效性和安全性。这将包括对氟西汀用于BN的评估，以及对Lisdexamfeamine用于床的评估。安全性信息将来自随机对照试验(RCT)、开放标签试验和病例报告。氟西汀用于BN和来塞非他明用于床是相对安全和耐受性良好的。尽管有这些特性，但这两种药物在饮食障碍的药物治疗中代表着有限的武器库。因此，需要更多基于研究的策略来开发安全、有效和更有针对性的饮食障碍治疗方法。
Eating disorders represent a set of psychiatric illnesses with lifelong complications and high relapse rates. Individuals with eating disorders are often stigmatized and clinicians have a limited set of treatments options. Pharmacotherapy has the potential to improve long term compliance and patient commitment to treatment for eating disorders. This review will examine the efficacy and safety profile of the FDA-approved medications for the treatment of bulimia nervosa (BN) and binge eating disorder (BED). This will include the evaluation of fluoxetine for BN, and lisdexamfetamine for BED. Safety information will be review from randomized control trials (RCT), open label trials, and case reports. Fluoxetine for BN and lisdexamfetamine for BED are relatively safe and well-tolerated. Despite these properties, these two medications represent a limited arsenal for the pharmacological treatment of eating disorders. Thus, more research-based strategies are needed to develop safe, effective, and more targeted therapies for eating disorders.
登录
查看更多内容
影响因子：
22.8
作者：
Dold, Markus;Aigner, Martin;Kasper, Siegfried
通讯作者：
Kasper, Siegfried
影响因子：
3.4
作者：
GARRIGOU, D;BROEKKAMP, CL;LLOYD, KG
通讯作者：
LLOYD, KG
影响因子：
2.9
作者：
Gasior, Maria;Hudson, James;McElroy, Susan L.
通讯作者：
McElroy, Susan L.
影响因子：
3.7
作者：
Guillaume, Sebastien;Jaussent, Isabelle;Schmidt, Ulrike
通讯作者：
Schmidt, Ulrike
影响因子：
6.7
作者：
Huas, C.;Caille, A.;Falissard, B.
通讯作者：
Falissard, B.